


TAPI-0

Cat. No.:	HY-118694
CAS No.:	163958-73-4
Molecular Formula:	C ₂₄ H ₃₂ N ₄ O ₅
Molecular Weight:	456.53
Target:	TNF Receptor; MMP; Bacterial
Pathway:	Apoptosis; Metabolic Enzyme/Protease; Anti-infection
Storage:	Sealed storage, away from moisture and light
	Powder -80°C 2 years
	-20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (109.52 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	2.1904 mL	10.9522 mL	21.9044 mL
		5 mM	0.4381 mL	2.1904 mL	4.3809 mL
	10 mM	0.2190 mL	1.0952 mL	2.1904 mL	
Please refer to the solubility information to select the appropriate solvent.					

BIOLOGICAL ACTIVITY

Description	TAPI-0 is a TACE (TNF- α converting enzyme; ADAM17) inhibitor with an IC ₅₀ of 100 nM. TAPI-0 is a MMP inhibitor and also attenuates TNF- α processing ^{[1][2]} .
IC₅₀ & Target	IC ₅₀ : 100 nM (TACE) ^[2]
In Vitro	TAPI-0 inhibits peptide deformylase (PDF) with an IC ₅₀ of 18 nM. TAPI-0 suppresses chlamydial growth by targeting the bacterial PDF ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Amit Balakrishnan, et al. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J Biol Chem. 2006 Jun 16;281(24):16691-9.

[2]. Shiori Haga, et al. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res. 2010 Mar;85(3):551-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA